secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-116280
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio reports Q3 net loss $14.1M; cash $160.3M, runway to Q2 2025
-------------------------------------------------------------------------

- Net loss of $14.1M ($0.37 per share) in Q3 2023, compared to $23.8M loss ($0.62 per share) in Q2 2023.
- Cash and cash equivalents $160.3M as of Sep 30, 2023; expects runway into Q2 2025.
- R&D expenses $15.1M in Q3, up from $13.5M in Q2, driven by VTP-300 HBV and VTP-850 trials.
- Upcoming milestones: interim data from two Phase 2 HBV trials at AASLD Nov 2023; Australia submission for VTP-1000 (celiac).
- Company changed name from Vaccitech to Barinthus Biotherapeutics in Nov 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923116280/0001104659-23-116280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923116280/tm2330270d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer